PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

apremilast Side Effects

The reactions most often reported to the FDA for apremilast (also sold as Otezla), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

143,174
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2012 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of apremilast come from 143,174 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 143,174 reports to the FDA Adverse Event Reporting System (FAERS) for apremilast (Otezla): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

143,174

Reports Mentioning Death

5,453

3.8% of reports — not proof the medicine caused the death

Hospitalizations

10,932

7.6% of reports

Top Indication

Psoriasis

Most Reported Adverse Reactions

DIARRHOEA
24,315
NAUSEA
21,927
PSORIASIS
20,247
HEADACHE
17,679
ABDOMINAL DISCOMFORT
8,065
PSORIATIC ARTHROPATHY
7,852
PAIN
6,595
RASH
6,479
VOMITING
6,346
ARTHRALGIA
6,226
FATIGUE
6,026
DEPRESSION
5,414
WEIGHT DECREASED
4,955
ABDOMINAL PAIN UPPER
4,760
PRODUCT DOSE OMISSION
4,594
MALAISE
4,477
PRURITUS
4,143

Who Reports Side Effects

Gender Distribution

Female 90,394 (66%)
Male 46,320 (34%)
Unknown 12

Age Distribution

0-17 403 (1%)
18-44 19,476 (25%)
45-64 40,417 (52%)
65-74 12,401 (16%)
75+ 5,085 (7%)

Reporting Trend by Year

12
13
14
15
16
17
18
19
20
21
22
23
24
25

Reactions in Death Reports

Top reactions reported in 5,453 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
SYSTEMIC LUPUS ERYTHEMATOSUS 1,750
TYPE 2 DIABETES MELLITUS 1,746
PSORIATIC ARTHROPATHY 1,731
GLOSSODYNIA 1,729
GENERAL PHYSICAL HEALTH DETERIORATION 1,721
RASH 1,714
SYNOVITIS 1,712
HYPOAESTHESIA 1,707
INFUSION RELATED REACTION 1,704
HYPERTENSION 1,703
RHEUMATOID ARTHRITIS 1,695
WOUND 1,677
HAND DEFORMITY 1,667
JOINT SWELLING 1,630
HEPATIC ENZYME INCREASED 1,621
FIBROMYALGIA 1,617
SWELLING 1,607
HELICOBACTER INFECTION 1,580
DUODENAL ULCER PERFORATION 1,578

Reactions in Hospitalization Reports

Top reactions in 10,932 reports where hospitalization was an outcome.

Reaction Reports
PSORIATIC ARTHROPATHY 2,086
RASH 2,053
FATIGUE 2,009
DIARRHOEA 1,929
RHEUMATOID ARTHRITIS 1,924
HEADACHE 1,920
NAUSEA 1,917
SYNOVITIS 1,894
PAIN 1,893
JOINT SWELLING 1,834
ARTHRALGIA 1,822
GENERAL PHYSICAL HEALTH DETERIORATION 1,798
VOMITING 1,795
INFUSION RELATED REACTION 1,779
HYPERTENSION 1,774
ARTHROPATHY 1,769
SYSTEMIC LUPUS ERYTHEMATOSUS 1,718
MALAISE 1,716

Compare apremilast vs adapalene →

What the FAERS Data Reveals About apremilast Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 143,174 voluntary reports linked to apremilast and its brand equivalents (Otezla), spanning 2012 through 2025. Of those, 5,453 (3.8%) listed death as an outcome and 10,932 (7.6%) involved hospitalization. The most common indication reported alongside adverse events was Psoriasis.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 66% were female and 34% male; age distribution skews toward 45-64, with 40,417 reports in that bracket. The single most reported reaction is diarrhoea with 24,315 submissions, followed by nausea and psoriasis.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.